| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Chamindie Punyadeera | Q61793588 |
| P2093 | author name string | Bryan W Day | |
| Benjamin Chua | |||
| Arutha Kulasinghe | |||
| Juliana Müller Bark | |||
| P2860 | cites work | Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers | Q24614672 |
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Focus on Extracellular Vesicles: Introducing the Next Small Big Thing | Q26767273 | ||
| Circulating tumour cells in metastatic head and neck cancers | Q26858916 | ||
| IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy. | Q48663479 | ||
| Clinical applications of the CellSearch platform in cancer patients | Q49885040 | ||
| Temozolomide Affects Extracellular Vesicles Released by Glioblastoma Cells | Q49904916 | ||
| DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme | Q49956296 | ||
| Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies | Q50100856 | ||
| Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. | Q51630365 | ||
| Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. | Q52092780 | ||
| Conventional and advanced magnetic resonance imaging in patients with high grade glioma. | Q52562075 | ||
| Current Challenges and Opportunities in Treating Glioblastoma. | Q52579808 | ||
| Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. | Q52646452 | ||
| Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. | Q52691741 | ||
| Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. | Q52875954 | ||
| Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. | Q53103689 | ||
| Immune Microenvironment in Glioblastoma Subtypes. | Q55261256 | ||
| Current state of immunotherapy for glioblastoma. | Q55457323 | ||
| High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q55460949 | ||
| Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escape. | Q55461135 | ||
| Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy. | Q55663886 | ||
| Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients | Q57025835 | ||
| Extracellular vesicles in cancer - implications for future improvements in cancer care | Q57143872 | ||
| Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts | Q57696186 | ||
| Current and future perspectives of liquid biopsies in genomics-driven oncology | Q58586693 | ||
| EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma | Q58605925 | ||
| Harnessing the immune system in glioblastoma | Q58609492 | ||
| Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models | Q58615751 | ||
| The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy | Q58788640 | ||
| Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis | Q60045517 | ||
| Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Q60326168 | ||
| Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding | Q61797489 | ||
| Non-Coding RNAs in Glioma | Q61814266 | ||
| Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid | Q62745703 | ||
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma | Q62745893 | ||
| Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets | Q64079042 | ||
| Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel | Q64106049 | ||
| Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer. | Q64996770 | ||
| Hypoxic glioblastoma release exosomal VEGF-A induce the permeability of blood-brain barrier | Q88772885 | ||
| Detection of circulating tumour cell clusters in human glioblastoma | Q90672790 | ||
| Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab | Q90788586 | ||
| Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma | Q91209309 | ||
| CSF DNA provides a snapshot of the glioma genome | Q91361600 | ||
| Neutrophils escort circulating tumour cells to enable cell cycle progression | Q91387375 | ||
| Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma | Q91451443 | ||
| Brain Tumor Microenvironment and Host State: Implications for Immunotherapy | Q91903287 | ||
| Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors | Q92263177 | ||
| The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring | Q92288374 | ||
| Immunotherapy for glioblastoma: quo vadis? | Q92341936 | ||
| Glioblastoma cancer stem cells: Biomarker and therapeutic advances | Q26859782 | ||
| Extracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patients | Q26861832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Gliomas and the vascular fragility of the blood brain barrier | Q28081953 | ||
| Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility | Q28082750 | ||
| Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases | Q28289395 | ||
| miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors | Q28307352 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Advanced magnetic resonance imaging of the physical processes in human glioblastoma | Q30847284 | ||
| Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations | Q30885944 | ||
| Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response | Q30907831 | ||
| Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay | Q34089398 | ||
| Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis | Q34111187 | ||
| Brain tumor cells in circulation are enriched for mesenchymal gene expression | Q34458631 | ||
| Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients | Q35028818 | ||
| Chemoresistance of glioblastoma cancer stem cells--much more complex than expected | Q35521316 | ||
| A fluid biopsy as investigating technology for the fluid phase of solid tumors. | Q35576451 | ||
| Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma | Q35788900 | ||
| The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients | Q35800375 | ||
| MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma | Q35803479 | ||
| Non-invasive real-time biopsy of intracranial lesions using short time expanded circulating tumor cells on glass slide: report of two cases | Q36097881 | ||
| Advanced MRI Techniques in the Monitoring of Treatment of Gliomas | Q36324977 | ||
| Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma | Q36560956 | ||
| Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. | Q36665167 | ||
| The biology and function of exosomes in cancer | Q36737945 | ||
| Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay | Q36962764 | ||
| MicroRNA-21 expression is associated with overall survival in patients with glioma | Q37600782 | ||
| A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool | Q37641229 | ||
| Circulating tumor cell is a common property of brain glioma and promotes the monitoring system | Q37687613 | ||
| DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. | Q37702107 | ||
| The disturbed blood-brain barrier in human glioblastoma | Q37990264 | ||
| Exosomes in tumor microenvironment influence cancer progression and metastasis | Q38091978 | ||
| Ectosomes and exosomes: shedding the confusion between extracellular vesicles | Q38356431 | ||
| Liquid biopsies in patients with diffuse glioma | Q38365590 | ||
| Glioblastoma: molecular pathways, stem cells and therapeutic targets | Q38393328 | ||
| Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging | Q38471533 | ||
| The biology of circulating tumor cells | Q38518846 | ||
| Circulating biomarkers for gliomas | Q38586617 | ||
| Emerging circulating biomarkers in glioblastoma: promises and challenges. | Q38591062 | ||
| Factors controlling permeability of the blood-brain barrier | Q38592449 | ||
| Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. | Q38771051 | ||
| Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics | Q38811002 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| Hematogenous dissemination of glioblastoma multiforme. | Q38969869 | ||
| Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms | Q39013275 | ||
| Liquid Biopsies, What We Do Not Know (Yet). | Q39135342 | ||
| Integrating liquid biopsies into the management of cancer | Q39157824 | ||
| Temozolomide: mechanisms of action, repair and resistance | Q39436413 | ||
| Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study | Q39598112 | ||
| MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7. | Q41138932 | ||
| Serum microRNA profiling in patients with glioblastoma: a survival analysis | Q42317085 | ||
| Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas | Q42366572 | ||
| The Role of ATRX in Glioma Biology | Q42369808 | ||
| Challenges in circulating tumour cell research | Q43500645 | ||
| Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients | Q45285546 | ||
| ATPS-73BIOLOGICAL ACTIVITY OF TUMOR-TREATING FIELDS (TTFIELDS) IN GLIOMA MODELS IN A PRECLINICAL SETTING. | Q45830621 | ||
| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution | Q46365334 | ||
| Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. | Q46410671 | ||
| Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy | Q46494412 | ||
| MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients | Q46619783 | ||
| Meta-analysis of the prognostic value of circulating tumor cells in breast cancer | Q47240978 | ||
| Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. | Q47827207 | ||
| Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients | Q47956458 | ||
| Liquid biopsy for brain tumors. | Q47963436 | ||
| CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. | Q47979443 | ||
| A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. | Q47998452 | ||
| MiR-21: A key player in glioblastoma pathogenesis. | Q48095332 | ||
| Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma | Q48106300 | ||
| Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. | Q48127393 | ||
| Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis | Q48155295 | ||
| A Collective Route to Head and Neck Cancer Metastasis | Q48240241 | ||
| Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients | Q48409555 | ||
| Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. | Q48533324 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | biomarker | Q864574 |
| brain tumor | Q233309 | ||
| glioblastoma | Q282142 | ||
| extracellular vesicle | Q21097485 | ||
| P304 | page(s) | 295-305 | |
| P577 | publication date | 2019-10-31 | |
| 2020-02-01 | |||
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Circulating biomarkers in patients with glioblastoma | |
| P478 | volume | 122 |
| Q90047247 | Analysis and Simulation of Glioblastoma Cell Lines-Derived Extracellular Vesicles Metabolome |
| Q89692421 | Comparison of paired cerebrospinal fluid and serum cell-free mitochondrial and nuclear DNA with copy number and fragment length |
| Q89879539 | Peptidylarginine Deiminase Isozyme-Specific PAD2, PAD3 and PAD4 Inhibitors Differentially Modulate Extracellular Vesicle Signatures and Cell Invasion in Two Glioblastoma Multiforme Cell Lines |
| Q102379423 | Proteomics analysis of serum small extracellular vesicles for the longitudinal study of a glioblastoma multiforme mouse model |
| Q91599145 | The Role of Circulating MicroRNA in Glioblastoma Liquid Biopsy |
Search more.